Pharmafile Logo
Pharmafocus logo
Advanced Search

Hodgkin lymphoma

Showing 6 posts of 6 posts found.

takeda_usa_pharmaceuticals_u

Takeda’s Adcetris secures expanded approval in Europe for untreated CD30+ Stage IV Hodgkin lymphoma

February 14, 2019
Sales and Marketing Adcetris, Cancer, Europe, Hodgkin lymphoma, Takeda, pharma

Takeda’s Adcetris (brentuximab vedotin) has seen its marketing authorisation expanded by the European Commission to include the treatment of previously …

News
merck_and_co

MSD’s Keytruda notches another FDA approval in Hodgkin lymphoma

March 15, 2017
Research and Development, Sales and Marketing Hodgkin lymphoma, MSD, keytruda

MSD, otherwise known as Merck in North America, continues to score indication successes with Keytruda, this time in Hodgkin lymphoma. …

News
cancer_cells

Survivors of Hodgkin lymphoma over twice as likely to suffer second cancer

March 14, 2017
Manufacturing and Production, Research and Development Hodgkin lymphoma, ICR

New research emerging from the Institute for Cancer Research (ICR) has found that those previously treated for Hodgkin lymphoma are …

News
opdivo_1

Opdivo nabs FDA approval in specific patients with Hodgkin lymphoma

May 18, 2016
Research and Development, Sales and Marketing Bristol-Myers Squibb, Hodgkin lymphoma, opdivo

Bristol-Myers Squibb (NYSE: BMY) has announced that the US Food and Drug Administration (FDA) has approved Opdivo (nivolumab) for the …

News
keytruda1

MSD receives fourth Breakthrough Therapy Designation for Keytruda

April 19, 2016
Manufacturing and Production, Research and Development Breakthrough Therapy Designation, FDA, Hodgkin lymphoma, MSD, Merck, breakthrough designation, breakthrough therapy, keytruda

MSD (NYSE: MRK) has announced that the US Food and Drug Administration has granted Breakthrough Therapy Designation to Keytruda (pembrolizumab) …

News

Takeda reveals five-year Adcetris survival data

December 6, 2015
Research and Development, Sales and Marketing Hodgkin lymphoma, Takeda, oncology

Takeda UK has announced post-treatment follow up data from the pivotal Phase II study of Adcetris revealing a five-year survival …

News

Latest content

Ardena announces €20m expansion following first GMP approval

April 19, 2024

Roche’s Alecensa approved by FDA as lung cancer treatment

April 19, 2024

GSK shares results from phase 3 trial for gonorrhoea treatment

April 18, 2024

Eli Lilly’s tirzepatide demonstrates efficacy in reducing sleep apnoea severity

April 18, 2024

Medincell and AbbVie enter agreement for development of next-generation injectables

April 17, 2024